• Congress looking into McKinsey's work with opioid makers

    Congress launched an investigation Nov. 5 into global consulting firm McKinsey's work with opioid manufacturers, The New York Times reported. 
  • Uncovering A Crucial Arrow in the Quiver to Fight Opioid Overdoses

    A revolution is quietly underway in the treatment of opioid addiction via the combination of medication-assisted treatment (MAT) and telemedicine. This innovative treatment, called teleMAT, takes traditional MAT to the next level. How? By making it easy to reach a physician proficient in addiction treatment while also avoiding the social stigma of being seen entering a doctor’s office.
  • Drugmakers not liable for opioid crisis in California, judge rules

    A California judge on Nov. 1 ruled that four drugmakers cannot be held liable for the state's opioid crisis, according to NPR.
  • HHS unveils new overdose prevention strategy

    HHS Secretary Xavier Becerra announced Oct. 27 a new overdose prevention strategy that is designed to boost access to care for those with substance use disorders and their families. 
  • Naloxone shortage could lead to thousands of avoidable overdose deaths

    A shortage of Pfizer's lifesaving overdose reversal drug naloxone could precipitate a surge in overdose deaths, North Carolina Health News reported Oct. 22.
  • Buprenorphine misuse on the decline, study finds

    Buprenorphine misuse in the U.S. has trended downward over four years, according to a National Institutes of Health study published in JAMA Network Open. 
  • Overdose deaths at new high, CDC data show

    More than 96,000 Americans died from drug overdoses in the 12-month period ending in March, marking a new record high, ​​according to preliminary CDC data released Oct. 13.
  • Tele-MAT Provides Light at the End of the Opioid Tunnel

    Pharmaceutical giant Johnson & Johnson just signed an agreement[1] with the state of New York in June to settle all of the state’s claims against the company related to the opioid epidemic in exchange for $263 million in funding for addiction treatment and related matters. This crucial development comes after a broader $5 billion settlement[2] between the company and many other states, and J&J’s own decision to stop selling opioids[3] altogether.
  • Pharmacy chains face 1st federal opioid trial: 7 things to know

    Four pharmacy chains are appearing in a federal courtroom in Cleveland on Oct. 4, marking the first time such companies have testified about their role in the country's opioid crisis.
  • Three pharma distributors to pay $75M to Cherokee Nation in opioid settlement

    AmerisourceBergen, Cardinal Health and McKesson said Sept. 28 they will pay a collective $75 million to the Cherokee Nation to settle opioid litigation. 
  • DEA issues rare alert as streets flooded by fake pills laced with fentanyl, meth

    The Drug Enforcement Administration on Sept. 27 issued its first safety alert in six years, warning about an "alarming increase" in fake prescription pills containing fentanyl and methamphetamine.
  • Methamphetamine overdose deaths nearly tripled in 4 years, NIH study finds

    Overdose deaths involving methamphetamine nearly tripled between 2015 and 2019 in people ages 18 to 64, according to a study published Sept. 22 in JAMA Psychiatry. 
  • OD deaths persist despite drop in opioid prescriptions, AMA says

    Opioid prescriptions fell 44.4 percent in the last decade, but the number of drug-related overdoses and deaths continued to increase, according to a report from the American Medical Association released Sept. 21. 
  • Justice Department appeals Purdue Pharma bankruptcy plan

    A division of the Justice Department filed an appeal Sept. 15 to block Purdue Pharma's bankruptcy plan, which was approved by a federal bankruptcy judge Sept. 1, NPR reported. 
  • Opioid deaths rising faster in Black community than other racial, ethnic groups, study finds

    Opioid related deaths are rising much faster in the Black population than other racial and eithnic groups, a study published Sept. 9 in The American Journal of Public Health found. 
  • Judge approves Purdue Pharma's bankruptcy plan

    Purdue Pharma's bankruptcy plan was approved by a federal judge Sept. 1, meaning the company that made and marketed the opioid Oxycontin will be dissolved, The New York Times reported.
  • Benzodiazepine-related overdoses on the rise, CDC says

    The U.S. experienced a spike in benzodiazepine-related overdoses in 2020, particularly in overdoses that involved illicit benzodiazepines such as etizolam and flubromazolam, according to a study released Aug. 26 by the CDC.
  • Sacklers say they'll abandon opioids settlement if not granted legal immunity

    The Sackler Family will pull out of Purdue Pharma's bankruptcy plan, which has been negotiated for two years and pledges $4.5 billion to combat the opioid epidemic, unless they are granted immunity from future opioid lawsuits, David Sackler, former board member, said in court Aug. 17.
  • Nearly half of pediatric opioid prescriptions are high risk

    Of the more than 4 million opioid prescriptions written for children and young adults under 21 in 2019, 45.6 percent fit high-risk patterns that could increase instances of misuse and overdose, according to a study published in the August 2021 issue of Pediatrics.
  • Why addiction risk algorithms could be making the opioid crisis worse

    The algorithms used by states' prescription monitoring systems sometimes block chronic pain sufferers from receiving opioids after inaccurately flagging them as potential addicts, Wired reported Aug. 11.

Featured Whitepapers

Featured Webinars